Frank Karbe - Net Worth and Insider Trading
Frank Karbe Net Worth
The estimated net worth of Frank Karbe is at least $8 Million dollars as of 2024-11-29. Frank Karbe is the Principal Fin'l & Accounting of Myovant Sciences Ltd and owns about 212,296 shares of Myovant Sciences Ltd (MYOV) stock worth over $6 Million. Frank Karbe is the EVP & CFO of Exelixis Inc and owns about 62,944 shares of Exelixis Inc (EXEL) stock worth over $2 Million. Frank Karbe is also the CEO of Better Therapeutics Inc and owns about 429,429 shares of Better Therapeutics Inc (BTTX) stock worth over $43. Details can be seen in Frank Karbe's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Frank Karbe has not made any transactions after 2023-07-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Frank Karbe
Frank Karbe Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Frank Karbe owns 8 companies in total, including Aduro Biotech Inc (ADRO) , Arbutus Biopharma Corp (ABUS) , and Exelixis Inc (EXEL) among others .
Click here to see the complete history of Frank Karbe’s form 4 insider trades.
Insider Ownership Summary of Frank Karbe
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ADRO | Aduro Biotech Inc | 2020-05-05 | director |
| ABUS | Arbutus Biopharma Corp | 2015-01-01 | director |
| EXEL | Exelixis Inc | 2010-08-24 | Senior VP & CFO |
 | | 2019-04-18 | director |
| | 2021-07-07 | Principal Fin'l & Accounting |
| | 2022-04-25 | director |
| | 2023-07-27 | director & See Remarks |
| | 2022-07-05 | director & See Remarks |
Frank Karbe Latest Holdings Summary
Frank Karbe currently owns a total of 3 stocks. Among these stocks, Frank Karbe owns 212,296 shares of Myovant Sciences Ltd (MYOV) as of July 7, 2021, with a value of $6 Million and a weighting of 71.69%. Frank Karbe owns 62,944 shares of Exelixis Inc (EXEL) as of August 24, 2010, with a value of $2 Million and a weighting of 28.31%. Frank Karbe also owns 429,429 shares of Better Therapeutics Inc (BTTX) as of July 27, 2023, with a value of $43 and a weighting of 0%.
Latest Holdings of Frank Karbe
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MYOV | Myovant Sciences Ltd | 2021-07-07 | 212,296 | 26.98 | 5,727,746 |
| EXEL | Exelixis Inc | 2010-08-24 | 62,944 | 35.93 | 2,261,578 |
| BTTX | Better Therapeutics Inc | 2023-07-27 | 429,429 | 0.00 | 43 |
Holding Weightings of Frank Karbe
Frank Karbe Form 4 Trading Tracker
According to the SEC Form 4 filings, Frank Karbe has made a total of 14 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years, including 0 buys and 14 sells. The most-recent trade in Myovant Sciences Ltd is the sale of 3,232 shares on July 7, 2021, which brought Frank Karbe around $70,296.
According to the SEC Form 4 filings, Frank Karbe has made a total of 0 transactions in Exelixis Inc (EXEL) over the past 5 years. The most-recent trade in Exelixis Inc is the acquisition of 16,500 shares on August 24, 2010, which cost Frank Karbe around $49,170.
According to the SEC Form 4 filings, Frank Karbe has made a total of 3 transactions in Better Therapeutics Inc (BTTX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Better Therapeutics Inc is the acquisition of 137,005 shares on July 27, 2023, which cost Frank Karbe around $100,014.
Insider Trading History of Frank Karbe
- 1
Frank Karbe Trading Performance
GuruFocus tracks the stock performance after each of Frank Karbe's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Frank Karbe is -5.36%. GuruFocus also compares Frank Karbe's trading performance to market benchmark return within the same time period. The performance of stocks bought by Frank Karbe within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Frank Karbe's insider trading performs compared to the benchmark.
Performance of Frank Karbe
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -7.95 | | | | | |
| Relative Return to S&P 500(%) | -5.79 | | | | | |
Frank Karbe Ownership Network
Frank Karbe Owned Company Details
What does Aduro Biotech Inc do?
Who are the key executives at Aduro Biotech Inc?
Frank Karbe is the director of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include director & President & CEO Eric Dobmeier , 10 percent owner Versant Voyageurs I, L.p. , and 10 percent owner Versant Voyageurs I Parallel, L.p. .
Aduro Biotech Inc (ADRO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aduro Biotech Inc Insider Transactions
Frank Karbe Mailing Address
Above is the net worth, insider trading, and ownership report for Frank Karbe. You might contact Frank Karbe via mailing address: C/o Myovant Sciences Inc., 2000 Sierra Point Parkway, 9th Floor, Brisbane Ca 94005.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
